European Heart Journal

Papers
(The H4-Index of European Heart Journal is 96. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure5399
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)5065
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2744
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2462
2021 ESC/EACTS Guidelines for the management of valvular heart disease2079
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension1028
2020 ESC Guidelines for the management of adult congenital heart disease916
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy846
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease781
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death736
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Internatio701
COVID-19 is, in the end, an endothelial disease665
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era647
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe469
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases445
Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage434
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy406
An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcircula382
Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection370
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors363
Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019350
Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study346
European Society of Cardiology: cardiovascular disease statistics 2021340
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis339
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research327
2023 ESC Guidelines for the management of acute coronary syndromes301
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery301
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Ather300
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus297
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement292
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study283
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force267
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance264
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial253
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine248
The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation248
C-reactive protein and clinical outcomes in patients with COVID-19242
COVID-19-related myocarditis in a 21-year-old female patient240
Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts225
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement211
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure206
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions203
Pulmonary embolism in COVID-19 patients: a French multicentre cohort study195
Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes190
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study186
2023 ESC Guidelines for the management of cardiomyopathies186
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyc184
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure o179
COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests178
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)167
Left bundle branch area pacing outcomes: the multicentre European MELOS study164
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation – Dual versus triple antithrombotic therapy164
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement155
The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials154
Prevalence of statin intolerance: a meta-analysis149
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)149
Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes143
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction141
The Mediterranean diet, plasma metabolome, and cardiovascular disease risk140
Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies139
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial137
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study137
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists136
Typical takotsubo syndrome triggered by SARS-CoV-2 infection136
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)135
Heart failure drug treatment: the fantastic four128
The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020128
The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults127
Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation126
Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial123
Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study121
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF119
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes118
Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank118
The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN)118
Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis117
Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank117
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial117
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial116
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials115
2023 ESC Guidelines for the management of endocarditis115
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery114
Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies113
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction112
Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism111
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme109
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial108
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial106
Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study104
Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study102
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes101
Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk101
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake101
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study96
EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic96
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry96
Vulnerable plaques and patients: state-of-the-art96
0.037722110748291